Blurbs

Analysts Offer Insights on Healthcare Companies: Prothena (PRTA), Nurix Therapeutics (NRIX) and Pacira Pharmaceuticals (PCRX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Prothena (PRTAResearch Report), Nurix Therapeutics (NRIXResearch Report) and Pacira Pharmaceuticals (PCRXResearch Report) with bullish sentiments.

Nurix Therapeutics (NRIX)

Needham analyst Gil Blum maintained a Buy rating on Nurix Therapeutics today and set a price target of $32.00. The company’s shares closed last Monday at $14.44.

According to TipRanks.com, Blum ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -20.0% and a 30.9% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Aeglea Biotherapeutics, and Rocket Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nurix Therapeutics with a $35.67 average price target, representing a 146.3% upside. In a report issued on November 7, Robert W. Baird also maintained a Buy rating on the stock with a $31.00 price target.

Pacira Pharmaceuticals (PCRX)

Needham analyst Serge Belanger maintained a Buy rating on Pacira Pharmaceuticals today and set a price target of $74.00. The company’s shares closed last Monday at $50.50, close to its 52-week low of $47.40.

According to TipRanks.com, Belanger is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.6% and a 40.1% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and KalVista Pharmaceuticals.

Pacira Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $73.71, a 38.8% upside from current levels. In a report issued on November 4, H.C. Wainwright also maintained a Buy rating on the stock with a $76.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on PRTA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More